Review
Open access
Aug 2026
The Efficacy and Safety of Dupilumab for Moderate-to-severe Asthma: A Systematic Review and Meta-analysis.
OBJECTIVE Asthma poses a heavy global health burden, and severe cases are poorly controlled by conventional therapy. Dupilumab is indicated for patients aged ≥6 years with severe eosinophilic or Type 2 asthma. Patients with different baseline characteristics may respond differently to this agent. Therefore, a comprehen...
Shunli Liu, Ya-Min Cao, Huiling Song et al.
· Journal of Asthma · 0 citations